The estimated Net Worth of George Golumbeski is at least $2.9 Milion dollars as of 5 May 2022. George Golumbeski owns over 8,000 units of Sage Therapeutics Inc stock worth over $59,920 and over the last 11 years he sold SAGE stock worth over $0. In addition, he makes $2,843,390 as Independent Director at Sage Therapeutics Inc.
George has made over 5 trades of the Sage Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 8,000 units of SAGE stock worth $251,600 on 5 May 2022.
The largest trade he's ever made was buying 28,330 units of Sage Therapeutics Inc stock on 26 April 2022 worth over $102,838. On average, George trades about 2,846 units every 39 days since 2014. As of 5 May 2022 he still owns at least 8,000 units of Sage Therapeutics Inc stock.
You can see the complete history of George Golumbeski stock trades at the bottom of the page.
Dr. George S. Golumbeski Ph.D. serves as Independent Director of the Company. Dr. Golumbeski previously served as the President of GRAIL, Inc., a health-care company focused on the early detection of cancer. From 2009 to 2018, Dr. Golumbeski was employed by Celgene Corporation, or Celgene, where he led all business development activities including in-licensing, mergers and acquisitions, and alliance management. Prior to Celgene, Dr. Golumbeski was Vice President of Business Development, Licensing, and Strategy at Novartis. Earlier in his career, he held leadership positions at Elan Pharmaceuticals Inc. and Schwarz Pharma AG, where he focused on neurology and neuropsychiatry therapeutics. Additionally, in the past five years, Dr. Golumbeski has served on the board of directors of Aura Biosciences, Inc., Carrick Therapeutics, KSQ Therapeutics, Inc., Shattuck Labs, Inc., Verseau Therapeutics, Inc., Enanta Pharmaceuticals, Inc. and MorphoSys AG. Dr. Golumbeski received a B.A. in Biology from the University of Virginia and a Ph.D. in Genetics from the University of Wisconsin—Madison. Golumbeski’s qualifications to sit on our Board of Directors include his years of experience in research and development, business development transactions and leadership at various pharmaceutical companies.
As the Independent Director of Sage Therapeutics Inc, the total compensation of George Golumbeski at Sage Therapeutics Inc is $2,843,390. There are 7 executives at Sage Therapeutics Inc getting paid more, with Jeffrey Jonas having the highest compensation of $9,902,080.
George's mailing address filed with the SEC is C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN, TX, 78701.
Over the last 10 years, insiders at Sage Therapeutics Inc have traded over $190,046,458 worth of Sage Therapeutics Inc stock and bought 150,092 units worth $6,260,297 . The most active insiders traders include Kevin P Starr, Robert Nelsen oraz Michael F Cola. On average, Sage Therapeutics Inc executives and independent directors trade stock every 32 days with the average trade being worth of $256,667. The most recent stock trade was executed by Kimi Iguchi on 2 January 2024, trading 1,642 units of SAGE stock currently worth $2,233.
sage therapeutics is a neuroscience-focused company developing medicines to treat life-threatening, rare cns disorders. our mission is to make life better for patients with central nervous systems diseases by discovering, developing, and delivering important new medicines to the market. to achieve that mission we leverage compelling science, a robust clinical foundation, strong partnerships, and a world-class team of founders, advisors, investors, scientists and managers. sage’s lead program, sage-547, is in clinical development for super-refractory status epilepticus (srse) and is the first of many compounds the company is developing in its portfolio of potential seizure medicines. sage’s robust chemistry platform has generated multiple new compounds that target the gabaa and nmda receptors, which have demonstrated preclinical activity. sage therapeutics is a private company launched in 2010 by an experienced team of r&d leaders, cns experts and investors.
Sage Therapeutics Inc executives and other stock owners filed with the SEC include: